Damage in a large systemic lupus erythematosus cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER) with emphasis on the cardiovascular system: a longitudinal analysis.


Journal

Lupus science & medicine
ISSN: 2053-8790
Titre abrégé: Lupus Sci Med
Pays: England
ID NLM: 101633705

Informations de publication

Date de publication:
03 Aug 2024
Historique:
received: 19 10 2023
accepted: 18 06 2024
medline: 4 8 2024
pubmed: 4 8 2024
entrez: 3 8 2024
Statut: epublish

Résumé

To assess organ damage, with emphasis on the cardiovascular system, over the different stages of the disease in a large SLE cohort. Multicentre, longitudinal study of a cohort of 4219 patients with SLE enrolled in the Spanish Society of Rheumatology Lupus Registry. Organ damage was ascertained using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). We longitudinally analysed SDI (globally and for each domain) over time only in the 1274 patients whose dates of damage events had been recorded. During the first year after diagnosis of SLE, 20% of the 1274 patients presented with new damage manifestations. At years 2 and 3, new damage was recorded in 11% and 9% of patients. The annual percentage of patients with new damage after year 5 decreased to 5%. In the first year with the disease, most damage was accumulated in the musculoskeletal, neuropsychiatric and renal systems; in later stages, most damage was in the musculoskeletal, ocular and cardiovascular systems. Considering 'cerebrovascular accident' and 'claudication for 6 months' as cardiovascular items, the cardiovascular system was the second most affected system during the early stages of SLE, with 19% of the patients who presented with damage affected at first year after diagnosis. During the late stages, 20-25% of the patients presenting with new damage did so in this modified cardiovascular domain of the SDI. New damage occurs mainly during the first year following diagnosis of SLE. Cardiovascular damage is relevant in both the early and the late stages of the disease. Strategies to prevent cardiovascular damage should be implemented early after diagnosis of SLE.

Identifiants

pubmed: 39097409
pii: 11/2/e001064
doi: 10.1136/lupus-2023-001064
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Irene Altabás-González (I)

Rheumatology Department, Vigo University Hospital Group, Vigo, Spain.
IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain.

Iñigo Rua-Figueroa (I)

Rheumatology, Hospital Universitario de Gran Canaria Dr Negrin, Las Palmas de Gran Canaria, Spain iruafer@gobiernodecanarias.org.

Coral Mouriño (C)

Rheumatology Department, Vigo University Hospital Group, Vigo, Spain.

Karen Roberts (K)

Rheumatology, Instituto de Investigación, Galicia Sur, External Statistical Advisor, Rosario, Argentina.

Norman Jimenez (N)

IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain.

Julia Martinez-Barrio (J)

Hospital General Universitario Gregorio Marañón, Madrid, Spain.

María Galindo (M)

Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain.

Jaime Calvo Alén (J)

Rheumatology, Hospital Universitario Araba, Vitoria-Gasteiz, Spain.

Victor Del Campo Pérez (VDC)

IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain.
Department of Epidemiology, Vigo University Hospital Group, Vigo, Spain.

Esther Uriarte Itzazelaia (E)

Department of Rheumatology, Donostia University Hospital Gipuzkoa Building, San Sebastian, Spain.

Eva Tomero (E)

Rheumatology Department, Hospital Universitario de la Princesa, Madrid, Spain.

Mercedes Freire-González (M)

Rheumatology, Academic Hospital Juan Canalejo de La Coruña Cardiology Service, A Coruna, Spain.

Víctor Martínez Taboada (V)

Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain.

Eva Salgado (E)

Rheumatology, Complejo Hospitalario de Orense, Ourense, Spain.

Paloma Vela (P)

Department of Rheumatology, Hospital General Universitario de Alicante, Alicante, Spain.

Antonio Fernandez-Nebro (A)

Rheumatology, Hospital Regional Universitario de Málaga, Malaga, Spain.

Alejandro Olivé (A)

Rheumatology Department, Hospital Universitario Germans Trias i Pujol, Badalona, Spain.

Javier Narváez (J)

Rheumatology, Hospital Universitario de Bellvitge, Hospitalet de LLobregat, Spain.

Raúl Menor-Almagro (R)

Rheumatology Service, Jerez Hospital, Jerez, Spain.

Gregorio Santos Soler (GS)

Department of Rheumatology, Hospital Villajoyosa, Alicante, Spain.

José Ángel Hernández-Beriain (JÁ)

Rheumatology, Hospital Insular of Gran Canaria, Gran Canaria, Spain.

Javier Manero (J)

Department of Rheumatology, Hospital Universitario Miguel Servet, Zaragoza, Spain.

Elena Aurrecoechea (E)

Rheumatology, Hospital Sierrallana, Torrelavega, Spain.

Oihane Ibarguengoitia-Barrena (O)

Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain.

Carlos Montilla (C)

Hospital Universitario de Salamanca, Salamanca, Spain.

Gema Bonilla (G)

Rheumatology, La Paz University Hospital, Madrid, Spain.

Vicenç Torrente-Segarra (V)

Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Sant Joan Despi, Spain.

Ana Paula Cacheda (AP)

Department of Rheumatology, Hospital Son Llatzer, Palma de Mallorca, Spain.

María Jesús García-Villanueva (MJ)

Hospital Universitario Ramon y Cajal, Madrid, Spain.

Claudia Moriano-Morales (C)

Department of Rheumatology, Hospital de León, León, Spain.

Concepción Fito Manteca (CF)

Department of Rheumatology, Universidad de Navarra-Campus Universitario, Pamplona, Spain.

Nuria Lozano-Rivas (N)

Rheumatology, Hospital Virgen de la Arrixaca, Murcia, Spain.

Cristina Bohórquez (C)

Department of Rheumatology, Hospital Universitario Príncipe de Asturias, Alcala de Henares, Spain.

José M Pego-Reigosa (JM)

Rheumatology Department, Vigo University Hospital Group, Vigo, Spain.
IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH